Wouter R Berger1, Eva R Meulendijks1, Jacqueline Limpens2, Nicoline W E van den Berg1, Jolien Neefs1, Antoine H G Driessen3, Sébastien P J Krul1, Wim Jan P van Boven3, Joris R de Groot4. 1. Amsterdam UMC, University of Amsterdam, Department of Cardiology, Heart Center, Meibergdreef 9, Amsterdam, the Netherlands. 2. Amsterdam UMC, University of Amsterdam, Medical Library, Meibergdreef 9, Amsterdam, the Netherlands. 3. Amsterdam UMC, University of Amsterdam, Department of Cardiothoracic Surgery, Heart Center, Meibergdreef 9, Amsterdam, the Netherlands. 4. Amsterdam UMC, University of Amsterdam, Department of Cardiology, Heart Center, Meibergdreef 9, Amsterdam, the Netherlands. Electronic address: j.r.degroot@amc.uva.nl.
Abstract
BACKGROUND: Persistent atrial fibrillation (AF) is associated with higher stroke and mortality risk than paroxysmal AF (pAF). Outcomes of catheter or surgical ablation are worse in patients with persistent AF than in pAF, and the optimal invasive rhythm control strategy has not been established. PURPOSE: We provide a contemporary systematic overview on efficacy and safety of catheter and minimally-invasive surgical ablation for persistent AF. METHODS: We systematically searched EMBASE, MEDLINE and CENTRAL from inception to July 2018 for randomized trials on surgical and catheter ablation, and included all study arms on persistent AF. Outcome was AF freedom after ≥12 months follow-up without AAD use. Random effects models were used to calculate proportions with 95%-confidence intervals. Safety consisted of adverse events during treatment and follow-up. RESULTS: We included 6 studies on minimally-invasive surgical ablation and 56 on catheter ablation, involving 7624 patients with persistent AF. AF Freedom at 12 months was 69% (95%CI 64-74%) after surgical and 51% (95%CI 46-56%) after catheter ablation. More severe procedural adverse events occurred with surgery than with catheter ablation. CONCLUSIONS: In persistent AF patients, minimally-invasive surgical ablation is associated with more procedural complications, but higher AF freedom. As adverse events after surgical ablation appear more severe than in catheter ablation, a patient-tailored therapy choice is warranted.
BACKGROUND: Persistent atrial fibrillation (AF) is associated with higher stroke and mortality risk than paroxysmal AF (pAF). Outcomes of catheter or surgical ablation are worse in patients with persistent AF than in pAF, and the optimal invasive rhythm control strategy has not been established. PURPOSE: We provide a contemporary systematic overview on efficacy and safety of catheter and minimally-invasive surgical ablation for persistent AF. METHODS: We systematically searched EMBASE, MEDLINE and CENTRAL from inception to July 2018 for randomized trials on surgical and catheter ablation, and included all study arms on persistent AF. Outcome was AF freedom after ≥12 months follow-up without AAD use. Random effects models were used to calculate proportions with 95%-confidence intervals. Safety consisted of adverse events during treatment and follow-up. RESULTS: We included 6 studies on minimally-invasive surgical ablation and 56 on catheter ablation, involving 7624 patients with persistent AF. AF Freedom at 12 months was 69% (95%CI 64-74%) after surgical and 51% (95%CI 46-56%) after catheter ablation. More severe procedural adverse events occurred with surgery than with catheter ablation. CONCLUSIONS: In persistent AFpatients, minimally-invasive surgical ablation is associated with more procedural complications, but higher AF freedom. As adverse events after surgical ablation appear more severe than in catheter ablation, a patient-tailored therapy choice is warranted.
Authors: William L Patrick; Zehang Chen; Jason J Han; Benjamin Smood; Akhil Rao; Fabliha Khurshan; Siddharth Yarlagadda; Amit Iyengar; John J Kelly; Joshua C Grimm; Marisa Cevasco; Joseph E Bavaria; Nimesh D Desai Journal: Cardiol Ther Date: 2022-03-31
Authors: Eva María Cirugeda Roldan; Sofía Calero; Víctor Manuel Hidalgo; José Enero; José Joaquín Rieta; Raúl Alcaraz Journal: Entropy (Basel) Date: 2020-07-07 Impact factor: 2.524
Authors: R Wesselink; J Neefs; N W E van den Berg; E R Meulendijks; M M Terpstra; M Kawasaki; F A Nariswari; F R Piersma; W J P van Boven; A H G Driessen; J R de Groot Journal: BMJ Open Date: 2022-03-09 Impact factor: 2.692
Authors: Jolien Neefs; Robin Wesselink; Nicoline W E van den Berg; Jonas S S G de Jong; Femke R Piersma; WimJan P van Boven; Antoine H G Driessen; Joris R de Groot Journal: J Interv Card Electrophysiol Date: 2021-09-16 Impact factor: 1.759
Authors: Francesco Matteucci; Bart Maesen; Carlo De Asmundis; Elham Bidar; Linda Micali; Gianmarco Parise; Jos G Maessen; Mark La Meir; Sandro Gelsomino Journal: Interact Cardiovasc Thorac Surg Date: 2021-06-28
Authors: Daniel Mol; Lisanne Renskers; Jippe C Balt; Rohit E Bhagwandien; Yuri Blaauw; Vincent J H M van Driel; Antoine H G Driessen; Arif Elvan; Richard Folkeringa; Rutger J Hassink; Bart Hooft van Huysduynen; Justin G L M Luermans; Jeroen Y Stevenhagen; Pepijn H van der Voort; Sjoerd W Westra; Joris R de Groot; Jonas S S G de Jong Journal: J Cardiovasc Electrophysiol Date: 2022-01-28 Impact factor: 2.942